Efficacy and safety of ABT-126, an α7 nicotinic cholinergic agonist, in treatment of cognitive impairment associated with schizophrenia: Results from a phase 2B study in smokers

Authors
Category Primary study
ConferenceSchizophrenia Bulletin
Year 2015
This article has no abstract
Epistemonikos ID: 352075d8fd4dc20361cc6eb9c5712f78d4b17b9c
First added on: Apr 30, 2026